Opexa Therapeutics (OPXA) Immune Monitoring Program Featured in Neurology Reviews
10/21/2013 9:32:17 AM
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company has been featured in Neurology Reviews. The article, titled "Regulation May Be Impaired in Patients With Secondary Progressive MS,” was written by Erik Greb, the publication's senior associate editor, and presents data from Opexa’s Immune Monitoring program that is part of its ongoing Phase IIb Abili-T trial in Secondary Progressive MS (SPMS).
Help employers find you! Check out all the jobs and post your resume.
comments powered by